Latest in EGFR-positive NSCLC with exon 20 insertion mutations

Bookmark and Share
Published: 9 Feb 2021
Views: 3608
Prof Sanjay Popat, Prof Michael Thomas, Dr Marina Garassino, Dr Rosario Campelo, Dr Enriqueta Felip

Prof Sanjay Popat (The Royal Marsden Hospital, London, UK) chairs an expert panel discussion with Prof Michael Thomas (University of Heidelberg, Heidelberg, Germany), Dr Marina Garassino (Istituto Nazionale dei Tumori Cancer Institute, Milan, Italy), Dr Rosario Campelo (University of A Coruña, A Coruña, Spain) and Dr Enriqueta Felip (Vall d’Hebron University Hospital, Barcelona, Spain) on the latest in EGFR-positive NSCLC with exon 20 insertion mutations.

Prof Popat initially discusses the treatment and management of patients with EGFR mutant NSCLC and the options currently available.

Dr Thomas discusses the treatment paradigms currently being used in Germany. They then talk about some of the new drugs that have currently been in the limelight i.e; amivantamab and mobocertinib and what it means for the patients.

Dr Garassino and Campelo give their expert opinion on it. Dr Felip talks about poziotinib and discusses the efficacy of osimertinib as well.

They mention the new data that was presented at WCLC 2020 and in the end talk about the future of the NSCLC patients with exon 20 insertions mutations.

This programme has been supported by an unrestricted educational grant from Janssen.